Benvenue Medical, Inc. is welcoming Thomas M. Prescott and Thomas C. Wilder to its Board of Directors. Prescott is president and CEO of Align Technology, Inc., and Thomas C. Wilder is president and CEO of Sequent Medical, Inc.
Thomas Prescott and Thomas Wilder Join Benvenue Board
1 min read Premium comments
Prescott, who will serve as chairman of the board, has been president and CEO of Align since 2002. The company is the inventor of Invisalign and an innovator in digital dentistry, and it has grown significantly under his leadership. Previously, Mr. Prescott was president and CEO of Cardiac Pathways, where he successfully led a turnaround prior to its acquisition by Boston Scientific Corporaton. Prior to Cardiac Pathways, Mr. Prescott held various sales, marketing, management and executive roles at Nellcor Puritan Bennett, GE Medical Systems, and Siemens.
Prescott earned a Master of Management from the Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree, with emphasis in Civil Engineering, from Arizona State University.
Tom Wilder has served as the president and CEO of Sequent Medical, Inc., a privately held medical device company focused on developing innovative devices for the treatment of neurovascular disease, since 2010.
Prior to joining Sequent Medical, Wilder was president and CEO of Photothera, Inc., a private company developing transcranial laser therapy for the treatment of acute ischemic stroke. His experience also include being president and CEO of Micro Therapeutics, a publicly traded company that provided a broad range of advanced interventional products to neurovascular specialists. Prior to Micro Therapeutics, Wilder held several management positions during an 11-year tenure at Medtronic, Inc.
He holds a Master of Management from the Kellogg Graduate School of Management at Northwestern University, and a BA in Economics from Stanford University. He also serves on the Board of Endologix, Inc.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.